Monte Stewart

As Canada eases restrictions on psychedelics, B.C.-based Numinus prepares for clinical trials

Monte Stewart
March 2, 2022

Numinus has received Health Canada approval to conduct a clinical trial to test the effects of MDMA, the amphetamine more commonly known as ecstasy, in the treatment of patients suffering from severe post-traumatic stress disorder.

... Please become a Member or login to read the rest of this article ...


Other stories mentioning these organizations, people and topics
Organizations: Health Canada, MAPS, MAPS Canada, and Numinus Wellness
People: Mark Haden, Neil Boyd, and Payton Nyquvest
Topics: drug discovery, healthcare, pharmaceutical clinical trials, and psychedelics

Other News

Government funding and policy are driving big carbon emissions reductions by steelmakers

Lessons from long-term care can inform innovation across Canada's healthcare system

The Short Report - March 2, 2022: Ottawa commits $240M for semiconductor industry, $45M for post-secondary research infrastructure, a good month for the space sector, and more

Four clean energy projects get $106M in federally-funded competition






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 0 free articles remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.